SuperworthRevvity profit margin RVTY
Gross, operating and net profit as a share of revenue over the last twelve months, from 2010.
- Net margin, 12 months
- 8.2%
- Operating margin, 12 months
- 12.3%
- Net margin on a year earlier
- −2.0 pts
- Peer median
- 9.9%
Over the twelve months to Jul 5, 2026, Revvity kept 8.2% of its revenue as net profit, with an operating margin of 12.3% and a gross margin of 55.0%.
Five years earlier its net margin was 24.4%.
The median for 10 diagnostics and research stocks of a similar size is 9.9%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 8.4% | 12.5% | 54.8% |
| FY2024 | 9.8% | 12.6% | 55.8% |
| FY2023 | 25.2% | 10.9% | 56.0% |
| FY2022 | 17.2% | 22.4% | 60.1% |
| FY2021 | 19.8% | 26.4% | 57.6% |
| FY2020 | 19.2% | 25.9% | 55.8% |
| FY2019 | 7.9% | 12.6% | 48.4% |
| FY2018 | 8.6% | 11.7% | 48.3% |
| FY2017 | 13.0% | 13.1% | 47.6% |
| FY2016 | 11.1% | 13.4% | 47.9% |
| FY2015 | 9.4% | 11.1% | 45.3% |
| FY2014 | 7.1% | 9.4% | 44.9% |
| FY2013 | 7.7% | 10.5% | 45.2% |
| FY2012 | 3.3% | 4.7% | 45.5% |
| FY2011 | 0.4% | 4.7% | 44.2% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 8.2% | −2.0 pts | 12.3% | |
| Q1 FY26 | 8.3% | −2.1 pts | 12.4% | |
| Q4 FY25 | 8.4% | −1.4 pts | 12.5% | |
| Q3 FY25 | 8.4% | −0.9 pts | 12.9% | |
| Q2 FY25 | 10.2% | +3.9 pts | 13.6% | |
| Q1 FY25 | 10.3% | +4.9 pts | 13.5% | |
| Q4 FY24 | 9.8% | −15.4 pts | 12.6% | |
| Q3 FY24 | 9.3% | −17.2 pts | 11.2% | |
| Q2 FY24 | 6.3% | −22.6 pts | 10.2% | |
| Q1 FY24 | 5.5% | −26.3 pts | 9.9% | |
| Q4 FY23 | 25.2% | +8.0 pts | 10.9% | |
| Q3 FY23 | 26.5% | +10.5 pts | 12.9% |
Against its peers
Companies in Medical - Diagnostics & Research nearest Revvity's size, closest first, today.
| Company | Profit margin |
|---|---|
| RVTYRevvity | 8.2% |
| MEDPMedpace | 17.7% |
| LHLabcorp | 7.0% |
| DGXQuest Diagnostics | 9.2% |
| BIOBio-Rad Laboratories | 8.6% |
| MTDMettler-Toledo International | 21.9% |
| CAICaris Life Sciences | 10.6% |
| ILMNIllumina | 18.4% |
| IDXXIDEXX Laboratories | 25.0% |
| WATWaters | 3.6% |
| IQVIQVIA | 8.1% |
| Peer median | 9.9% |
Where Revvity ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Revvity
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.